Can your triglycerides be 3000

Regardless of the cause, having very high triglycerides has been linked to a higher chance of developing heart disease and having a heart attack or stroke. While research is still underway to uncover the exact relationship between triglycerides and cardiovascular disease, we know that very high levels tend to cluster with other risk factors including being obese, high blood pressure, and high cholesterol.

Extremely high levels of triglycerides can also lead to pancreatitis, a very serious condition in which the pancreas becomes inflamed. This condition can cause significant pain and usually results in hospitalization.

For Clinicians. Loading results Very High Triglycerides. What are Triglycerides? Triglycerides are a type of fat lipid found in your blood. We and our partners process data to: Actively scan device characteristics for identification. I Accept Show Purposes. Table of Contents View All. Table of Contents. Triglyceride Basics. High Triglycerides and Atherosclerosis. What Causes High Triglycerides? Triglycerides and Stroke. Getting Triglycerides Under Control. Was this page helpful? Thanks for your feedback!

Sign Up. What are your concerns? Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Atherosclerosis and Stroke. American Heart Association. Association of serum lipid indices with large artery atherosclerotic stroke.

Lomitapide reduces the secretion of chylomicrons and VLDL. However, fatty liver, present before treatment, progressed to steatohepatitis and fibrosis after 12 to 13 years. Conclusions and Relevance Lomitapide prevented pancreatitis in severe intractable hypertriglyceridemia but at a potential long-term cost of hepatotoxicity.

Recurrent pancreatitis is a severe and potentially fatal complication of hypertriglyceridemia. To convert triglycerides to millimoles per liter, multiply by 0. Severe and very severe hypertriglyceridemia can be caused by several genetic defects that impair metabolism by lipoprotein lipase of triglycerides in chylomicrons and very low density lipoproteins VLDL.

Treatments that increase metabolism of triglycerides by lipoprotein lipase, such as fibrates or omega-3 fatty acids, are ineffective. Microsomal triglyceride transfer protein MTP transfers triglycerides and other lipids to apolipoprotein B48 in the enterocyte and apolipoprotein B in the hepatocyte, a necessary step to start the assembly of the lipid-protein complex in the enterocyte that will become a chylomicron or in the hepatocyte to become a VLDL or low-density lipoprotein LDL.

The patient was first hospitalized for pancreatitis at age 15 years. She was treated with a low-fat diet; gemfibrozil, mg; omega-3 fatty acids; and niacin, singly or in combination; without benefit. She had had pancreatitis during each of her 3 pregnancies, at ages 23, 33, and 34 years, 1 of which ended in miscarriage. For the next 11 years, she experienced chronic abdominal pain, and recurrent pancreatitis requiring 12 hospitalizations, in spite of maximal dietary and drug treatment.

At age 44 years, she experienced a near-fatal episode of pancreatitis complicated by hypotension and acute respiratory distress syndrome that required intubation.

A pancreatectomy was recommended as preventive treatment but was deferred to permit additional attempts at medical treatment. Her plasma was grossly lipemic. Abdominal ultrasonographic findings repeatedly showed fatty liver and splenomegaly. Computed tomographic CT scans showed no hepatomegaly or other liver abnormality. The patient did not have diabetes mellitus; her body weight was normal, with a body mass index, calculated as weight in kilograms divided by height in meters squared, of 21 to 22; and results from thyroid and renal tests were normal.

She rarely drank alcoholic beverages. To convert hematocrit to a proportion of 1, multiply by 0. Apolipoprotein B and B48 levels were both elevated. Five other siblings have moderate hypertriglyceridemia but without pancreatitis, suggesting that at least some of them may be heterozygous for the LPL PL mutation.

An emergency investigational new drug use and institutional review board approval for lomitapide were granted. Written informed consent was received. On June 7, , other lipid-lowering therapy was stopped, and treatment was initiated with lomitapide, which was the first use of an MTP inhibitor for hypertriglyceridemia.

The lomitapide dose was titrated to balance the triglyceride-lowering effect with avoidance of diarrhea presumably caused by fat malabsorption Figure 1. In , Aegerion reformulated lomitapide into mg and mg capsules. The dose of lomitapide was adjusted to balance efficacy and tolerability. Discontinued indicates temporary cessation of lomitapide. This time period is indicated by vertical gray columns.

In the 10th year, lomitapide was reformulated into and mg capsules. Christian, N. Bourgeois, R. Snipes, and K. Berglund, J. Brunzell, A. Goldberg et al. Melnick, S. Nazir, D. Gish, and M. Pejic and D. Vangara, K. Klingbeil, R. Fertig, and J. Brahm and R. View at: Google Scholar J.

Brunzell, W. Hazzard, D. Porte Jr. Berger, R. Quera, J. Poniachik, D. Oksenberg, and J. View at: Google Scholar M. Jabbar, M. Zuhri-Yafi, and J. Athyros, O. Giouleme, N. Nikolaidis et al. DiMagno and S. Feldman, L. Friedman, and L. Sleisenger, Eds. Saunders, St.